TY  - GEN
AU  - de la Torre-Tarazona, Humberto Erick
AU  - Passaes, Caroline
AU  - Moreno, Santiago
AU  - Sáez-Cirión, Asier
AU  - Alcamí, José
PY  - 2024
DO  - 10.1038/s41598-024-64902-y
UR  - https://hdl.handle.net/20.500.12105/26263
AB  - Maraviroc (MVC) is an antiretroviral drug capable of binding to CCR5 receptors and block HIV entry into target cells. Moreover, MVC can activate NF-kB pathway and induce viral transcription in HIV-infected cells, being proposed as a latency reversal...
LA  - eng
PB  - Nature Publishing Group
KW  - Activation markers
KW  - HIV latency
KW  - Latency reversal agents
KW  - Maraviroc
KW  - Metabolic rates
KW  - Adult
KW  - CCR5 Receptor Antagonists
KW  - CD4-Positive T-Lymphocytes
KW  - Cells, Cultured
KW  - Cyclohexanes
KW  - Glycolysis
KW  - HIV Infections
KW  - HIV-1
KW  - Humans
KW  - Lymphocyte Activation
KW  - Male
KW  - Maraviroc
KW  - Triazoles
TI  - High concentrations of Maraviroc do not alter immunological and metabolic parameters of CD4 T cells
TY  - research article
ER  -